Abstract
Several studies demonstrate the efficacy of short- and long-term Sandostatin® treatment in acromegaly administered subcutaneously at doses ranging from 150 to 300 µg up to 600 µg per day [1, 3, 5, 7–10]. A rhythm of 3 injections per day has been shown to reduce the magnitude of the re-elevation of growth hormone (GH) which occurs before the following injection when Sandostatin is given only twice daily. However, some patients fail to respond adequately to the above-mentioned doses thus pointing to the possible need for higher doses of Sandostatin [1] or continuous subcutaneous infusion.
Participating Centers: P. Allanic, Y. Lorcy/Rennes, B. Charbonnel/ Nantes, P. Fossati, D. Dewailly, O. VerrierMine/Lille, Ph. Jacquet/Marseille, J. P. Louvet, A. Bennet/Toulouse, J. Lubetzki, Ph. Chanson, J. Timsit, A. Warnet/Paris, J. Mirouze, M. Rodier/Montpellier, H. Rousset, B. Estour/St. Etienne, G. Sassolas, J. P. Casez, P. Serusclat/ Lyon, M. Simon, G. Edan, J. P. Hespel/Rennes Trial coordination: A. G. Harris (Basle), A. Deidier (Rueil-Malmaison)
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Barnard LG, Grantham WG, Lamberton P, O’Dorisio TM, Jackson IMD (1986) Treatment of resistant acromegaly with a long-acting Somatostatin analogue (SMS 201-995). Ann Intern Med 105: 856–861
Chanson P, Timsit J, Benoit O, Augendre B, Boulonguet M, Guillausseau PJ, Warnet A, Lubetzki J (1968) Rapid improvement in sleep apnoea of acromegaly after short-term treatment with somatostatin analogue SMS 201-995. Lancet ii: 1270–1271
Ch’ng LJC, Sandler LM, Kraenzlin ME, Burin JM, Joplin CF, Bloom SR (1985) Long-term treatment of acromegaly with a long-acting analogue of somatostatin. Br Med J 290: 284–288
Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD (1987) Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med 317: 12–17
Comi RJ, Gorden P (1987) The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocrinol Metab 64: 37–42
Daughaday W (1985) A new treatment for an old disease. N Engl J Med 313: 1604–1605
Lamberts SWJ, Oosterom R, Neufeld M, Del Pozo E (1985) The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60: 1161–1170
Lamberts SJ, Uitterlinden P, Del Pozo E (1987) SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegaly for over two years. J Clin Endocrinol Metab 65: 703–710
Lamberts SWJ, Uitterlinden P. Verschoor L, van Dongen KJ, Del Pozo E (1985) Longterm treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 313:1576— 1580
Plewe G, Beyer J, Krause U, Neufeld M, Del Pozo E (1984) Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet II: 782–784
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag, Berlin Heidelberg
About this paper
Cite this paper
Sassolas, G. et al. (1988). Effects of Long-Term Administration of Sandostatin® (SMS 201–995) at Increasing Doses in 40 Acromegalic Patients. Results from the French Sandostatin Acromegaly Study Group. In: Lamberts, S.W.J. (eds) Sandostatin® in the Treatment of Acromegaly. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73694-0_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-73694-0_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73696-4
Online ISBN: 978-3-642-73694-0
eBook Packages: Springer Book Archive